FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016505516> ?p ?o ?g. }

• W2016505516 endingPage "20730" @default.
• W2016505516 startingPage "20724" @default.
• W2016505516 abstract "The human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for integration of viral DNA into host cell chromatin. We have reported previously (Priet, S., Navarro, J. M., Gros, N., Querat, G., and Sire, J. (2003) J. Biol. Chem. 278, 4566–4571) that IN also plays a role in the packaging of the host uracil DNA glycosylase UNG2 into viral particles and that the region of IN encompassing residues 170–180 was responsible for the interaction with UNG2 and for its packaging into virions. In this work, we aimed to investigate the replication of HIV-1 viruses rendered deficient in virion-associated UNG2 by single or double point mutations in the region 170–180 of IN. We show that the L172A/K173A IN mutant virus was deficient for UNG2 packaging and was defective for replication because of a blockage at the stage of proviral DNA integration in host cell DNA. In vitro assays using long term repeat mimics, however, demonstrate that the L172A/K173A IN mutant was catalytically active. Moreover, trans-complementation experiments show that the viral propagation of L172A/K173A viruses could be rescued by the overexpression of Vpr·L172A/K173A IN fusion protein in a dose-dependent manner and that this rescue is independent of UNG2 packaging. Altogether, our data indicate that L172A/K173A mutations of IN induce a subtle defect in the function of IN, which nevertheless dramatically impairs viral replication. Unexpectedly, this blockage of replication could be overcome by forcing the packaging of higher amounts of this same mutated integrase. This is the first study reporting that blockage of the integration process of HIV-1 provirus carrying a mutation of IN could be alleviated by increasing amounts of IN even carrying the same mutations. The human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for integration of viral DNA into host cell chromatin. We have reported previously (Priet, S., Navarro, J. M., Gros, N., Querat, G., and Sire, J. (2003) J. Biol. Chem. 278, 4566–4571) that IN also plays a role in the packaging of the host uracil DNA glycosylase UNG2 into viral particles and that the region of IN encompassing residues 170–180 was responsible for the interaction with UNG2 and for its packaging into virions. In this work, we aimed to investigate the replication of HIV-1 viruses rendered deficient in virion-associated UNG2 by single or double point mutations in the region 170–180 of IN. We show that the L172A/K173A IN mutant virus was deficient for UNG2 packaging and was defective for replication because of a blockage at the stage of proviral DNA integration in host cell DNA. In vitro assays using long term repeat mimics, however, demonstrate that the L172A/K173A IN mutant was catalytically active. Moreover, trans-complementation experiments show that the viral propagation of L172A/K173A viruses could be rescued by the overexpression of Vpr·L172A/K173A IN fusion protein in a dose-dependent manner and that this rescue is independent of UNG2 packaging. Altogether, our data indicate that L172A/K173A mutations of IN induce a subtle defect in the function of IN, which nevertheless dramatically impairs viral replication. Unexpectedly, this blockage of replication could be overcome by forcing the packaging of higher amounts of this same mutated integrase. This is the first study reporting that blockage of the integration process of HIV-1 provirus carrying a mutation of IN could be alleviated by increasing amounts of IN even carrying the same mutations. HIV-1 1The abbreviations used are: HIV-1, human immunodeficiency virus, type 1; IN, integrase; ΔIN, IN minus; CA, capsid; LTR, long terminal repeat; UNG2, uracil DNA glycosylase; GST, glutathione S-transferase; TCID50, 50% tissue culture infective dose. integrase (IN) is an essential component required for the persistence of infection in vivo. IN is incorporated into viral particles as a part of the Gag-Pol precursor polyprotein that contains Gag (matrix, capsid (CA), nucleocapsid NCp7, and p6) and Pol (protease, reverse transcriptase, and IN) domains. Each of these domains is expressed individually upon proteolytic processing of the precursor by the viral protease. The functional role of IN is to catalyze the integration of the viral genome into the cellular genome through a two-step process that includes processing of the viral LTR ends and integration (reviewed by Ref. 1Craigie R. J. Biol. Chem. 2001; 276: 23213-23216Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). The processing step removes the terminal TG dinucleotide at each 3′-end of the proviral genome generating recessed 3′-ends. The integration step allows the nucleophilic attack of the host DNA by the recessed 3′-OH group in a trans-esterification reaction. Mutational analysis of IN identified distinct functional domains within the protein. The N-terminal domain (residues 1 to 50) contains a highly conserved HHCC motif that binds zinc (2Zheng, R., Jenkins, T. M., and Craigie, R. (Proc. Natl. Acad. Sci. U. S. A., 93, 13659–1366.Google Scholar, 3Bushman F.D. Engelman A. Palmer I. Wingfield P. Craigie R. Proc. Natl. Acad. Sci. U. S. A. 1993; 90 (1996): 3428-3443Crossref PubMed Scopus (331) Google Scholar, 4Cai M. Zheng R. Caffrey M. Craigie R. Clore G.M. Gronenborn A.M. Nat. Struct. Biol. 1997; 4: 567-577Crossref PubMed Scopus (305) Google Scholar). The catalytic core domain spans residues 51–212 and contains the invariant residues Asp-64, Asp-116, and Glu-152 (5Drelich M. Wilhelm R. Mous J. Virology. 1992; 188: 459-468Crossref PubMed Scopus (173) Google Scholar, 6Engelman A. Craigie R. J. Virol. 1992; 66: 6361-6369Crossref PubMed Google Scholar, 7Kulkosky J. Jones K.S. Katz R.A. Mack J.P. Skalka A.M. Mol. Cell. Biol. 1992; 12: 2331-2338Crossref PubMed Scopus (515) Google Scholar, 8LaFemina R.L. Schneider C.L. Robbins H.L. Callahan P.L. LeGrow K. Roth E. Schleif W.A. Emini E.A. J. Virol. 1992; 66: 7414-7419Crossref PubMed Google Scholar, 9van Gent D.C. Groeneger A.A. Plasterk R.H. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 9598-9602Crossref PubMed Scopus (180) Google Scholar). The C-terminal domain (residues 213–288) binds to the viral DNA and also possesses nonspecific DNA binding properties (10Khan E. Mack J.P. Katz R.A. Kulkosky J. Skalka A.M. Nucleic Acids Res. 1991; 19: 851-860Crossref PubMed Scopus (244) Google Scholar, 11LaFemina R.L. Callahan P.L. Cordingley M.G. J. Virol. 1991; 65: 5624-5630Crossref PubMed Google Scholar, 12Miller M.D. Farnet C.M. Bushman F.D. J. Virol. 1997; 71: 5382-5390Crossref PubMed Google Scholar, 13Mumm S.R. Grandgenett D.P. J. Virol. 1991; 65: 1160-1167Crossref PubMed Google Scholar, 14van Gent D.C. Vink C. Groeneger A.A. Plasterk R.H. EMBO J. 1993; 12: 3261-3267Crossref PubMed Scopus (211) Google Scholar). Genetic studies have indicated that mutations in IN affect multiple and distinct steps in the replication cycle, including protein maturation, virion morphology, uncoating, reverse transcription, and integration per se, revealing multiple consequences of altered IN in the viral life cycle (15Engelman A. Adv. Virus Res. 1999; 52: 411-426Crossref PubMed Google Scholar). Although in vitro studies have demonstrated that IN alone is sufficient to promote the integration process (1Craigie R. J. Biol. Chem. 2001; 276: 23213-23216Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar), lines of evidence indicate that other viral and cellular proteins can regulate this process. For example, it has been reported that NCp7 might influence the coupled joining by promoting DNA distortion (16Carteau S. Gorelick R.J. Bushman F.D. J. Virol. 1999; 73: 6670-6679Crossref PubMed Google Scholar) and that reverse transcriptase might play a role in blocking the auto-integration process (17Oz I. Avidan O. Hizi A. Biochem. J. 2002; 361: 557-566Crossref PubMed Google Scholar). Host proteins, upon association with IN, have also been reported to improve in vitro viral DNA integration. The barrier-to-autointegration factor (BAF) acts as an inhibitor to the undesirable autointegration process (18Harris D. Engelman A. J. Biol. Chem. 2000; 275: 39671-39677Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar), and the HMGI(Y) protein stimulates concerted viral DNA integration (19Farnet C.M. Bushman F.D. Cell. 1997; 88: 483-492Abstract Full Text Full Text PDF PubMed Scopus (296) Google Scholar). DNA-dependent protein kinase has been reported to be involved in the completion of the integration process (20Daniel R. Katz R.A. Skalka A.M. Science. 1999; 284: 644-647Crossref PubMed Scopus (222) Google Scholar). In some cases host proteins, such as the integrase inhibitor 1 (Ini1) factor or the uracil DNA glycosylase (UNG2) enzyme, interact with IN and are specifically incorporated into viral particles (21Yung E. Sorin M. Pal A. Craig E. Morozov A. Delattre O. Kappes J. Ott D. Kalpana G.V. Nat. Med. 2001; 7: 920-926Crossref PubMed Scopus (125) Google Scholar, 22Willetts K.E. Rey F. Agostini I. Navarro J.M. Baudat Y. Vigne R. Sire J. J. Virol. 1999; 73: 1682-1688Crossref PubMed Google Scholar). In a previous study, we demonstrated that leucine residue 172 of IN was important for the packaging of the host UNG2 enzyme (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). We have shown that virion-associated UNG2 plays a role similar to its cellular counterpart and participates in the correction of G:U mispairs to G:C pairs. The present study was designed to investigate whether the presence of UNG2 inside viral particles was required for efficient viral replication. We used a series of viruses mutated for each of the residues encompassing the region 170–181 of the α5 helix of IN, which is located outside of the catalytic triad of aspartic acid and glutamic acid residues, the D, D(35)E sequence motif. This series of mutations enabled us to classify viruses as deficient or proficient for UNG2 packaging (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). Our results show the following. i) Viruses with IN mutated at residues 172/173, 174, 178, and 180/181 are impaired for replication. ii) The failure to replicate of viruses with mutations at residues 174, 178, and 180/181, but not of those with mutations at residues 172/173, correlates with a loss of the in vitro catalytic activity of IN. iii) Although IN with mutation at residues 172/173 still retains its enzymatic activity, the integration process of L172A/K173A viruses is abrogated in the context of infection. iv) Finally, overexpression in trans of VPR·L172A/K173A IN fusion protein rescues, in a dose-dependent manner, the replication of L172A/K173A viruses, indicating that the defect of cis IN mutated viruses was compensated by increasing amounts of mutated IN. Altogether, our data point out the importance of leucine residue 172 in the viral integration process and UNG2 packaging. Plasmid Construction—The construction of IN mutated viruses has been described previously (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). DNA fragments each containing IN mutations were also PCR amplified and cloned into BamHI-XhoI sites of pGEX 5X2 (Amersham Biosciences) in order to generate plasmids expressing GST·IN fusion proteins. For trans-complementation experiments, the pLR2P-Vpr-IN expression vector kindly provided by J. Kappes (24Liu H. Wu X. Xiao H. Conway J.A. Kappes J.C. J. Virol. 1997; 71: 7704-7710Crossref PubMed Google Scholar) was used. Each of the IN mutations was introduced into this plasmid by PCR procedures in order to generate pLR2P-Vpr-IN mutants. The entire sequence of each mutated IN was checked by DNA sequencing. In the pLR2P-Vpr-IN vector, the Vpr gene was also mutated (W54G) to prevent any interaction between Vpr and UNG2, and the vector was used to construct Vpr(W54G)-IN(L172A/K173A) double mutant fusion. As a control, a Vpr-only expression vector was constructed by introducing a stop codon at the end of the Vpr reading frame in the pLR2P-Vpr-IN vector. Cell Lines, Transfection, and Infection—Human 293T cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with antibiotics and 10% fetal calf serum. The SupT1, H9, and C8166 cell lines were cultured in RPMI 1640 medium (Invitrogen) supplemented with antibiotics and 10% fetal calf serum. Viral stocks were produced by transfection of each of the proviral DNAs into subconfluent 293T cells with the FuGENE 6 transfectant reagent (Roche Applied Science) according to the manufacturer's protocol. For viral replication studies, SupT1 cells were infected with viral stocks obtained from the cell-free supernatant of transfected 293T cells and calibrated for equivalent amounts of CA p24 antigen by HIV-1 p24 antigen capture assay kit (Coulter). Propagation of viral infection was followed by measuring the reverse transcriptase activity in cell-free supernatants twice a week. For trans-complementation studies, provirus expression plasmids were cotransfected in 293T cells at a ratio of 2:1 with pLR2P-Vpr-IN expression vectors. Viral supernatants were then calibrated for similar amounts of CA p24 antigen by an HIV-1 p24 antigen capture assay kit. Serial 5-fold dilutions were used to infect the C8166 indicator cell line. The infectivity of trans-complemented viruses was calculated by the Reed-Muench method (25Burleson D.G. Johnson A. Salin M. Mason Jr., A.D. Pruitt Jr., B.A. Proc. Soc. Exp. Biol. Med. 1992; 199: 305-310Crossref PubMed Scopus (13) Google Scholar) to determine the 50% tissue culture infective dose (TCID50). Expression of Vpr·IN fusion proteins in trans-complemented viruses was analyzed by Western blot with rabbit polyclonal anti-IN antibody (a gift from D. Trono). Similar amounts of trans-complemented viruses were used as judged by the level of CA p24 antigen in the viral lysate revealed by Western blot with sheep polyclonal anti-p24 antibody (Aalto Bio Reagents, Rathfarnham-Dublin, Ireland). The presence of UNG2 was revealed by Western blot using anti-UNG2 antibody kindly provided by G. Slupphaug. Purification of Viruses—Viral particles released in the cell-free supernatant of transfected cells were collected by ultracentrifugation and highly purified through 8–18% Optiprep density gradient as described (26Dettenhofer M. Yu X.F. J. Virol. 1999; 73: 1460-1467Crossref PubMed Google Scholar). Gradient fractions coinciding with the peak of the reverse transcriptase activity were pooled and normalized for equivalent amounts of the CA p24 antigen. Viral lysate was obtained by lysis of purified virions in TNE buffer (10 mm Tris-HCl, pH 7.5, 100 mm NaCl, and 1 mm EDTA) in the presence of 0.2% of Triton X-100. In Vitro Catalytic Activity of IN—GST·IN fusion proteins were expressed in Epicurian Coli BL21-codonPlus RIL (Stratagene) and purified on glutathione-agarose beads as reported previously (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). GST derivatives were eluted from agarose beads in the presence of 20 mm glutathione, and the purity of proteins was estimated by Coomassie Blue staining. The amounts of GST derivatives were quantified by comparison with the bovine serum albumin (BSA) standard. The oligonucleotide pair used for processing activity measurement was 71 (5′-GTGTGGAAAATCTCTAGCAGT-3′) and 72 (5′-ACTGCTAGAGATTTTGCACAC-3′). The oligonucleotide pair used for strand transfer activity measurement was 70 (5′-GTGTGGAAAATCTCTAGCA-3′) and 72. Oligonucleotides 70 and 71 were 5′-end labeled with T4 polynucleotide kinase in the presence of [γ-32P]ATP and purified through Microspin G25 columns (Amersham Biosciences) before annealing to oligonucleotide 72. IN catalytic activity was assayed essentially as described (27Chow S.A. Vincent K.A. Ellison V. Brown P.O. Science. 1992; 255: 723-726Crossref PubMed Scopus (359) Google Scholar). Briefly, 200 nm of each GST derivative were incubated with 10 nm of the appropriate set of oligonucleotides in a final volume of 20 μl of a buffer containing 20 mm Hepes, pH 7.2, 1 mm dithiothreitol, and 10 mm MnCl2. After an incubation of 1 h at 37 °C, the reactions were stopped by the addition of 20 mm EDTA, and DNA products were recovered by ethanol precipitation in the presence of 10 μg of tRNA carrier. DNA products of the 3′-processing and DNA strand transfer reactions were dried and dissolved in 10 μl of 95% formamide loading dye. The samples were separated on 8 m urea, 15% polyacrylamide denaturating gels in 1× TBE. Gels were fixed in 10% acetic acid, and radiolabeled products were visualized by autoradiography. Where indicated, increasing amounts (5, 25, and 100 nm)ofGST·wild-type IN and GST·L172A/K173A IN were used in the assay. Determination of Viral DNA Integration—Viral stocks from transfected 293T cells were filtered through 0.45-μm pore size filters and treated with DNase I (20 μg/ml) for 30 min at 37 °C in the presence of 10 mm MgCl2. H9 cells (106) were infected for 2 h by spinoculation (28O'Doherty U. Swiggard W.J. Malim M.H. J. Virol. 2000; 74: 10074-10080Crossref PubMed Scopus (563) Google Scholar) with equal amounts of IN mutant viruses; then cells were washed extensively with phosphate-buffered saline and cultured for 18 additional hours. The total DNA was isolated from the infected cells by the QIAamp DNA Mini Kit protocol (Qiagen) and eluted with 200 μl of elution buffer. Viral DNA products corresponding to the different steps of retrotranscription were assessed by quantitative real-time PCR as described in literature (29Butler S.L. Hansen M.S. Bushman F.D. Nat. Med. 2001; 7: 631-634Crossref PubMed Scopus (577) Google Scholar). Real-time PCR was performed with an ABI PRISM 7000 apparatus (Applied Biosystems) using PCR primers and TaqMan probes described previously (29Butler S.L. Hansen M.S. Bushman F.D. Nat. Med. 2001; 7: 631-634Crossref PubMed Scopus (577) Google Scholar). The integrated forms of proviral DNA were assessed using a two-step PCR amplification with 5′ Alu primer (5′-TCCCAGCTACTGGGGAGGCTGAGG-3′) and L1 primer (5′-AGGCAAGCTTTATTGAGGCTTAGGC-3′) followed by nested PCR with L2 primer (5′-CTGTGGATCTACCACACACAAGGCTAC-3′) and L3 primer (5′-GCTGCTTATATGTAGCATCTGAGGGC-3′) as described (30Wu Y. Marsh J.W. Science. 2001; 293: 1503-1506Crossref PubMed Scopus (304) Google Scholar). Propagation of IN Mutant Viruses in Infected Cell Culture—In a previous report (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar) we showed that residues encompassing the region 170–181 of IN were critical for host UNG2 packaging. We performed alanine-scanning mutagenesis and delineated the residues responsible for UNG2 packaging (Fig. 1). In this study we investigated the replication of UNG2-deficient or UNG2-proficient viruses. Each of the IN mutated viruses was examined for replication in infected cells. Viral stocks were produced from 293T cells transfected with each IN mutant proviral DNA. Transfected cells yielded mutated viruses at a level corresponding to 80–100% of the wild-type level, suggesting that mutations in IN did not seem to affect virion assembly and release (data not shown). Similar amounts of viruses, as estimated by CA p24 antigen measurement, were used to infect Sup T1 cells, and propagation of infection was monitored by measuring the reverse transcriptase activity in the cell-free supernatant of infected cells twice a week. As shown in Fig. 2, viruses carrying mutations at residues 170/171 or 176/177 displayed wild-type kinetics of replication. In contrast, viruses with mutations 172/173, 174, 178, or 180/181 did not replicate at all. This complete failure to replicate is reminiscent of viruses with a defect at the integration stage of the proviral genome and suggests that the catalytic properties of mutated IN could be altered.Fig. 2Replication kinetics of wild-type and IN mutant viruses. Viruses produced in the cell-free supernatant of 293T cells transfected with each of proviral DNAs were harvested, calibrated for similar amounts of CA p24 antigen, and used to infect Sup T1 cells. Virus production was monitored by measuring the reverse transcriptase (RT) activity in the cell-free supernatant twice a week.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Catalytic Activity of IN Mutants—We therefore investigated whether disrupting some residues of the region 170–181 of IN affects its catalytic function. We measured processing and integration steps by using in vitro assays with similar amounts of purified GST·IN proteins. For these assays, IN mutant proteins fused in N terminus to GST were purified from bacterial lysate and incubated with appropriate oligonucleotides. The presence of faster migrating DNA species is the hallmark of the processing process (Fig. 3, top panel), and the presence of slower-migrating DNA species is the hallmark of the integration process (Fig. 3, bottom panel). As a negative control, we used the GST·IN protein with a missense mutation (D116A) in the catalytic core domain of IN, impairing the integration process (6Engelman A. Craigie R. J. Virol. 1992; 66: 6361-6369Crossref PubMed Google Scholar). Results showed that IN proteins with mutations at residues 170/171, 172/173, and 176/177 behaved as wild-type (Fig. 3). In contrast, IN with mutations at residues 174, 178, or 180/181 was enzymatically inactive, explaining why viruses carrying these mutations failed to replicate. Intriguingly, the L172A/K173A IN protein exhibited wild-type catalytic activity, although this mutation in the context of HIV-1 virus infection was shown to impair replication. A provirus bearing the single point mutation L172A was constructed, and results of the infectivity study showed that residue L172A alone was responsible for both UNG2 packaging (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar) and the defect of replication (not shown). Impaired Integration Process of L172A/K173A Viruses—We next examined which step(s) of the viral life cycle, including reverse transcription, nuclear import, and integration processes, was altered in cells infected with L172A/K173A viruses. H9 cells were infected with similar amounts of viruses from the DNase I-treated cell-free supernatant of transfected cells, and, 18 h post-infection, viral DNA from wild-type or IN mutated viruses produced during the unique cycle of infection was extracted and amplified with appropriate primer pairs. Using real-time PCR to quantify the amounts of reverse transcription intermediate DNA products (R-U5, R-Gag, and 2-LTR circles), we detected similar amounts of completed products of reverse transcription in cells infected with either wild-type, D116A, or L172A/K173A viruses (data not shown), indicating that viral DNA synthesis and nuclear entry were unaffected. We then measured the integration process by evaluating proviral integration events using an Alu LTR PCR assay with primers corresponding to the viral LTR and the repetitive Alu sequences present in the cellular DNA. Results in Fig. 4 show the complete absence of integrated DNA products for D116A and L172A/K173A viruses in contrast to wild-type viruses, indicating that the L172A/K173A virus was defective at the integration step, although its integrase was demonstrated to be functional in the LTR mimic assays in vitro. Rescue of the Replication of L172A/K173A Viruses—To address whether replication of L172A/K173A viruses could be restored, we used a previously reported experimental system (24Liu H. Wu X. Xiao H. Conway J.A. Kappes J.C. J. Virol. 1997; 71: 7704-7710Crossref PubMed Google Scholar, 31Fletcher III, T.M. Soares M.A. McPhearson S. Hui H. Wiskerchen M. Muesing M.A. Shaw G.M. Leavitt A.D. Boeke J.D. Hahn B.H. EMBO J. 1997; 16: 5123-5138Crossref PubMed Scopus (88) Google Scholar, 32Liu H. Wu X. Xiao H. Kappes J.C. J. Virol. 1999; 73: 8831-8836Crossref PubMed Google Scholar, 33Wu X. Liu H. Xiao H. Kim J. Seshaiah P. Natsoulis G. Boeke J.D. Hahn B.H. Kappes J.C. J. Virol. 1995; 69: 3389-3398Crossref PubMed Google Scholar, 34Wu X. Liu H. Xiao H. Conway J.A. Hunter E. Kappes J.C. EMBO J. 1997; 16: 5113-5122Crossref PubMed Scopus (91) Google Scholar) in which IN protein was incorporated in trans into viral particles via a fusion with HIV-1 Vpr (Fig. 5A). It has been reported that proviruses mutated in one domain of IN can be rescued by trans-expressed IN containing mutations in another domain (14van Gent D.C. Vink C. Groeneger A.A. Plasterk R.H. EMBO J. 1993; 12: 3261-3267Crossref PubMed Scopus (211) Google Scholar). This successful trans-complementation was indeed due to the ability of INs to oligomerize each subunit, providing distinct functions to obtain a wild-type IN phenotype. Viral stocks were generated by cotransfection of D116A, IN minus (ΔIN), or L172A/K173A proviral DNA together with expression vectors encoding VPR·wild-type IN, VPR·L172A/K173A IN, or VPR·D116A IN fusion proteins. The C8166 indicator cell line was infected with serial 5-fold dilutions of viral stocks. The infectivity of trans-complemented viruses was measured by the number of cell-forming syncytia and expressed as the TCID50. Expression of Vpr·IN fusion proteins in trans-complemented viral particles was demonstrated by Western blotting (Fig. 5B). The apparently higher levels of IN in trans-complemented viruses, compared with non-trans-complemented viruses, is likely due to proteolytic cleavage of the Vpr·IN protein by the viral protease. As expected, the trans-expression of wild-type IN rescued the replication of the ΔIN, L172A/K173A, and D116A viruses (Fig. 5C). The trans-expression of D116A IN, which is catalytically incompetent, restored the replication of L172A/K173A viruses but not that of ΔIN and D116A viruses. Conversely, trans-expression of L172A/K173A IN has the capacity to rescue the replication of D116A and ΔIN viruses up to ∼50% of that shown with trans wild-type IN. Unexpectedly, trans-complementation experiments showed that trans L172A/K173A IN can rescue the propagation of L172A/K173A viruses, although both cis- and trans-expressed IN proteins carried the same mutation. This restoration is approximately twice less efficient than that observed with trans wild-type IN, whatever the cis-expressed viruses. Altogether, these results suggest that mutations of residues 172 and 173 of IN fused to Vpr did not alter the catalytic property of IN. The Rescue of Replication Is Independent of UNG2 Packaging—Previous studies have reported that Vpr associates with UNG2 (35Bouhamdan M. Benichou S. Rey F. Navarro J.M. Agostini I. Spire B. Camonis J. Slupphaug G. Vigne R. Benarous R. Sire J. J. Virol. 1996; 70: 697-704Crossref PubMed Google Scholar) and that Vpr can promote the packaging of overexpressed HA-tagged UNG2 into viral particles (36Mansky L.M. Preveral S. Selig L. Benarous R. Benichou S. J. Virol. 2000; 74: 7039-7047Crossref PubMed Scopus (157) Google Scholar). To investigate whether the rescue of L172A/K173A viruses might be due to the packaging of host UNG2 via the Vpr portion within the Vpr·IN fusion protein, we analyzed the presence of packaged UNG2 into highly purified ΔIN viruses trans-complemented with either Vpr·IN or VPR·L172A/K173A IN. Results presented in Fig. 6 show that ΔIN virus was devoid of detectable endogenous UNG2 and that neither Vpr fusions with wild-type IN nor those with mutated IN were able to direct a substantial packaging of UNG2. As a control, similar amounts of the HIV-1 wild-type virus were analyzed and showed the presence of packaged UNG2. These data indicate that IN promoted UNG2 packaging in the context of the Gag-Pol polyprotein but not in the context of a Vpr·IN fusion. To ascertain that no UNG2 packaging was responsible for the rescue, we performed trans-complementation assays with a Vpr·IN fusion protein, containing Vpr mutated at tryptophan 54, fused to L172A/K173A IN. The W54R and W54G mutations have been shown to abolish the interaction with UNG2 (36Mansky L.M. Preveral S. Selig L. Benarous R. Benichou S. J. Virol. 2000; 74: 7039-7047Crossref PubMed Scopus (157) Google Scholar). 2S. Priet, J.-M. Navarro, G. Quérat, and J. Sire, unpublished data. Our results indicate that the W54G·VPR·L172A/K173A IN fusion protein rescued the viral propagation of L172A/K173A viruses to the same extent as the wild-type VPR·L172A/K173A IN fusion protein, demonstrating that the Vpr-UNG2 association was not involved in the successful rescue of L172A/K173A viruses (data not shown). Trans-complementation of cis L172A/K173A Viruses by trans L172A/K173A IN Is Dose-dependent—To understand how the overexpression of L172A/K173A IN can rescue the propagation of L172A/K173A viruses, we carried out trans-complementation experiments with increasing amounts of wild-type and L172A/K173A IN fusion proteins. The expression level of fused proteins in both cell lysate and viral particles was analyzed by Western blot (Fig. 7A). Trans-complementation of L172A/K173A viruses with increased doses of trans wild-type or L172A/K173A IN proteins led to a dose-dependent rescue of viral propagation (Fig. 7B). These data indicate that the failure to replicate of L172A/K173A viruses could be compensated by increasing amounts of trans L172A/K173A IN protein delivered into viral particles. To demonstrate that IN alone, and not IN-associated proteins, was involved in the rescue of L172A/K173A viruses, we performed in vitro experiments wherein the catalytic activity of increasing amounts of recombinant L172A/K173A IN was compared with that of wild-type IN. As shown in Fig. 8, both the processing and DNA strand transfer of L172A/K173A IN fusion protein, although this latter was catalytically active, were nevertheless ∼4 times less efficient than those of wild-type IN. These in vitro results are consistent with in vivo results showing that trans L172A/K173A IN in infected cells rescues the replication of cis L172A/K173A viruses in a dosedependent manner. In a previous report (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar), we analyzed a series of HIV-1 viruses with point mutations in the 170–181 region of IN to determine which residues of IN were important for host UNG2 packaging. We demonstrated that leucine residue 172, and not adjacent residues, was required for the incorporation of UNG2 into viral particles. In this study, we have investigated the replicative properties of HIV-1 viruses deficient or proficient for the presence of UNG2 in viral particles. We showed that UNG2-proficient viruses (E170A/H171A and V176A/Q177A viruses) replicated as wild-type viruses, except those whose mutations induced severe alterations of the catalytic activity of IN (T174A, M178A, and V180A/F181A viruses). In contrast, the UNG2-deficient virus (L172A/K173A IN mutant virus) failed to replicate and was impaired at the stage of integration of proviral DNA into host cell chromatin. In trans-complementation assays, proviruses mutated in one domain of IN can be rescued by trans-expressed IN containing a mutation in another domain (14van Gent D.C. Vink C. Groeneger A.A. Plasterk R.H. EMBO J. 1993; 12: 3261-3267Crossref PubMed Scopus (211) Google Scholar). This trans-complementation was due to the ability of INs to oligomerize, each subunit providing distinct functions to obtain a wild-type IN phenotype. The replication defect of viruses carrying the L172A/K173A IN mutation can be rescued by the coexpression in trans of the catalytically incompetent D116A IN protein, indicating that the two mutated IN proteins retain their ability to oligomerize and that the defect of the L172A/K173A IN viruses was compensated by the presence of the wild-type leucine 172 residue in D116A. Therefore, the replication blockage of L172A/K173A viruses was not due to alteration of the catalytic properties of the mutated IN per se. Remarkably, these L172A/K173A viruses were also rescued by dose-dependent trans-expression of the same mutated IN. These data correlate well with the integration assays using LTR mimics in vitro, which show that four times more L172A/K173A IN than wild-type IN was required to achieve a similar integration pattern. Because the first step of the integration reaction, namely the processing of the 3′-ends of the LTR mimics, is affected, we propose that mutated IN is less efficient in binding to the LTR ends. This weakness in LTR binding was alleviated by allowing a higher concentration of mutated IN. We propose that the integration process is a rate-limiting process in the natural course of HIV-1 infection. It is possible that the integration activity of viruses with the L172A/K173A IN mutation is just below the threshold. A slight enhancement of the expression of IN in infected cells, even carrying the same mutation, might surpass the threshold and lead to the restoration of the integration process. In trans-complementation assays, we observed that host UNG2 could not be packaged by the Vpr·IN fusion despite being clearly dependent on the presence of IN in the context of the Gag-Pol precursor. We can speculate on two hypotheses, which are not mutually exclusive. First, the folding of IN processed from the Vpr fusion protein may not accurately reflect the folding of IN processed from the Gag-Pol precursor, leading to differential bindings of UNG2. Such a differential in binding between INs deriving from either the Vpr·IN fusion or the Gag-Pol precursor has been reported in the case of the HA-S6 trans dominant mutant of the integrase interactor 1 (Ini 1) (21Yung E. Sorin M. Pal A. Craig E. Morozov A. Delattre O. Kappes J. Ott D. Kalpana G.V. Nat. Med. 2001; 7: 920-926Crossref PubMed Scopus (125) Google Scholar). Second, although the IN domain of the Gag-Pol precursor is required for UNG2 packaging, it may not be sufficient. Indeed, we have reported previously that UNG2 can also bind viral reverse transcriptase (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). It may be that a triple interaction between UNG2 and both the reverse transcriptase and IN domains of the Gag-Pol precursor is necessary to allow the efficient packaging of UNG2. Because the L172A/K173A mutation led to a severe blockage in provirus integration in vivo, we were unable to follow the replication of the sole UNG2-deficient virus over many replicative cycles. The integration defect could be rescued in trans by overexpression of IN, either wild-type or mutated, but it allowed only one replicative cycle. However, we have previously reported (23Priet S. Navarro J.M. Gros N. Querat G. Sire J. J. Biol. Chem. 2003; 278: 4566-4571Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar) that wild-type but not UNG2-deficient viruses have the ability to repair G:U mispairs, suggesting a role of UNG2 in the control of the accuracy of reverse transcription. If the rescued proviral DNA is riddled with G to A mutations due to unprocessed uracils in the absence of packaged UNG2, that would lead to impair replication in subsequent passages of the virus. The role of the virion-associated UNG2 enzyme in the viral life cycle remains an open question and will require studies of viral replication in UNG2-deficient T cells. In conclusion, we have investigated the replicative properties of UNG2-deficient or -proficient IN mutant viruses in order to study the role of packaged UNG2 in the viral life cycle. We have not been able to draw definite conclusions about the importance of UNG2 for HIV-1 replication, but we have found an interesting mutant of IN that could be rescued by allowing a higher concentration of the very same mutant integrase in the viral particle. Whether the mutation L172A/K173K leads to a reduced affinity of IN for its LTR substrate or to another undefined defect remains to be investigated. We thank R. Vigne for critically reading the manuscript and J. C. Kappes, M. Malim, and D. Trono for the generous gift of reagents." @default.
• W2016505516 created "2016-06-24" @default.
• W2016505516 creator A5044460125 @default.
• W2016505516 creator A5049415937 @default.
• W2016505516 creator A5051028664 @default.
• W2016505516 creator A5080215094 @default.
• W2016505516 date "2003-06-01" @default.
• W2016505516 modified "2023-09-28" @default.
• W2016505516 title "Reversion of the Lethal Phenotype of an HIV-1 Integrase Mutant Virus by Overexpression of the Same Integrase Mutant Protein" @default.
• W2016505516 cites W1480613123 @default.
• W2016505516 cites W1517131856 @default.
• W2016505516 cites W1572231208 @default.
• W2016505516 cites W1591356060 @default.
• W2016505516 cites W1664638011 @default.
• W2016505516 cites W1685289055 @default.
• W2016505516 cites W1770932653 @default.
• W2016505516 cites W1846959000 @default.
• W2016505516 cites W1919588791 @default.
• W2016505516 cites W1978909186 @default.
• W2016505516 cites W1979989142 @default.
• W2016505516 cites W1984675480 @default.
• W2016505516 cites W1995455922 @default.
• W2016505516 cites W2005663970 @default.
• W2016505516 cites W2014265802 @default.
• W2016505516 cites W2020555083 @default.
• W2016505516 cites W2025972928 @default.
• W2016505516 cites W2026184248 @default.
• W2016505516 cites W2032891258 @default.
• W2016505516 cites W2048116817 @default.
• W2016505516 cites W2059229106 @default.
• W2016505516 cites W2078061657 @default.
• W2016505516 cites W2082737070 @default.
• W2016505516 cites W2097074859 @default.
• W2016505516 cites W2100265029 @default.
• W2016505516 cites W2103113774 @default.
• W2016505516 cites W2105648514 @default.
• W2016505516 cites W2114021619 @default.
• W2016505516 cites W2117759649 @default.
• W2016505516 cites W2120185624 @default.
• W2016505516 cites W2131222990 @default.
• W2016505516 cites W2158227880 @default.
• W2016505516 cites W2164859620 @default.
• W2016505516 cites W2169196764 @default.
• W2016505516 cites W4243002328 @default.
• W2016505516 doi "https://doi.org/10.1074/jbc.m301768200" @default.
• W2016505516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12670953" @default.
• W2016505516 hasPublicationYear "2003" @default.
• W2016505516 type Work @default.
• W2016505516 sameAs 2016505516 @default.
• W2016505516 citedByCount "19" @default.
• W2016505516 countsByYear W20165055162014 @default.
• W2016505516 countsByYear W20165055162015 @default.
• W2016505516 crossrefType "journal-article" @default.
• W2016505516 hasAuthorship W2016505516A5044460125 @default.
• W2016505516 hasAuthorship W2016505516A5049415937 @default.
• W2016505516 hasAuthorship W2016505516A5051028664 @default.
• W2016505516 hasAuthorship W2016505516A5080215094 @default.
• W2016505516 hasBestOaLocation W20165055161 @default.
• W2016505516 hasConcept C104317684 @default.
• W2016505516 hasConcept C127716648 @default.
• W2016505516 hasConcept C142462285 @default.
• W2016505516 hasConcept C143065580 @default.
• W2016505516 hasConcept C14430832 @default.
• W2016505516 hasConcept C153911025 @default.
• W2016505516 hasConcept C159047783 @default.
• W2016505516 hasConcept C2522874641 @default.
• W2016505516 hasConcept C2777302000 @default.
• W2016505516 hasConcept C2993143319 @default.
• W2016505516 hasConcept C3013748606 @default.
• W2016505516 hasConcept C501734568 @default.
• W2016505516 hasConcept C54355233 @default.
• W2016505516 hasConcept C70883133 @default.
• W2016505516 hasConcept C86803240 @default.
• W2016505516 hasConceptScore W2016505516C104317684 @default.
• W2016505516 hasConceptScore W2016505516C127716648 @default.
• W2016505516 hasConceptScore W2016505516C142462285 @default.
• W2016505516 hasConceptScore W2016505516C143065580 @default.
• W2016505516 hasConceptScore W2016505516C14430832 @default.
• W2016505516 hasConceptScore W2016505516C153911025 @default.
• W2016505516 hasConceptScore W2016505516C159047783 @default.
• W2016505516 hasConceptScore W2016505516C2522874641 @default.
• W2016505516 hasConceptScore W2016505516C2777302000 @default.
• W2016505516 hasConceptScore W2016505516C2993143319 @default.
• W2016505516 hasConceptScore W2016505516C3013748606 @default.
• W2016505516 hasConceptScore W2016505516C501734568 @default.
• W2016505516 hasConceptScore W2016505516C54355233 @default.
• W2016505516 hasConceptScore W2016505516C70883133 @default.
• W2016505516 hasConceptScore W2016505516C86803240 @default.
• W2016505516 hasIssue "23" @default.
• W2016505516 hasLocation W20165055161 @default.
• W2016505516 hasOpenAccess W2016505516 @default.
• W2016505516 hasPrimaryLocation W20165055161 @default.
• W2016505516 hasRelatedWork W1565901822 @default.
• W2016505516 hasRelatedWork W1892544028 @default.
• W2016505516 hasRelatedWork W1987599063 @default.
• W2016505516 hasRelatedWork W2016505516 @default.
• W2016505516 hasRelatedWork W2059214751 @default.
• W2016505516 hasRelatedWork W2060397969 @default.

• next